147 related articles for article (PubMed ID: 3384359)
1. Effect and mechanism of action of isosorbide-5-mononitrate.
Hayes PC; Westaby D; Williams R
Gut; 1988 Jun; 29(6):752-5. PubMed ID: 3384359
[TBL] [Abstract][Full Text] [Related]
2. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis.
Escorsell A; Feu F; Bordas JM; García-Pagán JC; Luca A; Bosch J; Rodés J
J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728
[TBL] [Abstract][Full Text] [Related]
3. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function.
Navasa M; Chesta J; Bosch J; Rodés J
Gastroenterology; 1989 Apr; 96(4):1110-8. PubMed ID: 2925055
[TBL] [Abstract][Full Text] [Related]
4. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension.
García-Pagán JC; Feu F; Navasa M; Bru C; Ruiz del Arbol L; Bosch J; Rodés J
J Hepatol; 1990 Sep; 11(2):189-95. PubMed ID: 2123914
[TBL] [Abstract][Full Text] [Related]
5. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis.
Grose RD; Plevris JN; Redhead DN; Bouchier IA; Hayes PC
J Hepatol; 1994 Apr; 20(4):542-7. PubMed ID: 8051395
[TBL] [Abstract][Full Text] [Related]
6. [Propranolol and 5-isosorbide mononitrate in patients with cirrhosis: systemic and portal hemodynamic events].
Castaño G; Viudez P; Sookoian S; Carlevaro O; Riccitelli M; Frider B
Gastroenterol Hepatol; 2000; 23(6):275-81. PubMed ID: 15324622
[TBL] [Abstract][Full Text] [Related]
7. Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension.
Piscaglia F; Donati G; Gaiani S; Gramantieri L; Leoni S; Mancini M; Bolondi L
Dig Liver Dis; 2004 Sep; 36(9):594-602. PubMed ID: 15460844
[TBL] [Abstract][Full Text] [Related]
8. Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertension.
Mols P; Hallemans R; Melot C; Lejeune P; Naeije R
J Hepatol; 1989 May; 8(3):316-24. PubMed ID: 2732445
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of isosorbide-5-mononitrate in reducing portal pressure in cirrhotic patients with cirrhosis and portal hypertension.
Jenkins SA; Shields R
J Gastroenterol Hepatol; 1991; 6(1):91-3. PubMed ID: 1883984
[No Abstract] [Full Text] [Related]
10. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD
Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
[TBL] [Abstract][Full Text] [Related]
11. Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis.
Merkel C; Finucci G; Zuin R; Bazzerla G; Bolognesi M; Sacerdoti D; Gatta A
J Hepatol; 1987 Apr; 4(2):174-80. PubMed ID: 3584925
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis.
Garcia-Pagán JC; Navasa M; Bosch J; Bru C; Pizcueta P; Rodés J
Hepatology; 1990 Feb; 11(2):230-8. PubMed ID: 2307401
[TBL] [Abstract][Full Text] [Related]
13. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects.
Morillas RM; Planas R; Cabré E; Galán A; Quer JC; Feu F; García Pagán JC; Bosch J; Gassull MA
Hepatology; 1994 Dec; 20(6):1502-8. PubMed ID: 7982651
[TBL] [Abstract][Full Text] [Related]
14. Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic patients.
Bolognesi M; Sacerdoti D; Merkel C; Gatta A
J Ultrasound Med; 1994 Dec; 13(12):945-52. PubMed ID: 7877205
[TBL] [Abstract][Full Text] [Related]
15. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study.
García-Pagán JC; Feu F; Bosch J; Rodés J
Ann Intern Med; 1991 May; 114(10):869-73. PubMed ID: 2014947
[TBL] [Abstract][Full Text] [Related]
16. Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis.
Tsai YT; Lee FY; Lin HC; Chang TT; Lay CS; Wang SS; Kong CW; Lee SD; Lo KJ
Hepatology; 1989 Sep; 10(3):283-7. PubMed ID: 2759546
[TBL] [Abstract][Full Text] [Related]
17. Effect of peroral administration of isosorbide dinitrate on portal pressure and blood flow in patients with cirrhosis of the liver.
Cervinka J; Kordac V; Kalab M
J Int Med Res; 1989; 17(6):560-4. PubMed ID: 2628133
[TBL] [Abstract][Full Text] [Related]
18. Effect of sublingual isosorbide dinitrate in portal hypertension.
Bhatia SJ; Deshmukh H; Abraham P; Shah AV; Vontivillu JA; Jagasia DH; Kothari RH
Indian J Gastroenterol; 1990 Apr; 9(2):113-5. PubMed ID: 2323797
[TBL] [Abstract][Full Text] [Related]
19. Reduction of portal pressure by chronic administration of isosorbide dinitrate in patients with cirrhosis: effects on systemic and splanchnic hemodynamics and liver function.
Ikegami M; Toyonaga A; Tanikawa K
Am J Gastroenterol; 1992 Sep; 87(9):1160-4. PubMed ID: 1519573
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201-995) and low-dose isosorbide dinitrate on portal hypertension in conscious cirrhotic rats.
Hori N; Okanoue T; Sawa Y; Itoh Y; Mori T; Takami S; Kashima K
J Gastroenterol; 1994 Aug; 29(4):460-8. PubMed ID: 7951857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
